INTRODUCTION
The role of aberrant promoter methylation of tumor suppressor genes in a variety of human malignancies has been of great interest (1, 2) . Current techniques for analysis of methylation status are based on bisulfite modification of genomic DNA. Because sodium bisulfite treatment exclusively converts unmethylated cytosines to uracils under appropriate conditions (3) , subsequent analysis to distinguish cytosines from uracils enables us to know the methylation status. Although methylationspecific PCR (MSP) (4) is widely used for the analysis of a limited number of CpG sites, it does not fulfill a need for quantitative methylation analysis. On the other hand, bisulfite genomic sequencing (5,6) provides semiquantitative information of a methylation status within an amplified region. However, it requires large-scale sequencing of multiple plasmid clones. There are several other methods to quantitate CpG methylation density, such as combined bisulfite restriction analysis (COBRA) (7), real-time PCR-based methods, (8) (9) (10) , bisulfite-based single nucleotide primer extension-ion pair reverse phase highperformance liquid chromatography (bisulfite-SNuPE-IP RP HPLC) assay (11) , bisulfite PCR single-stranded conformational polymorphism (BiPS) analysis (12) , and enzymatic regional methylation assay (ERMA) (13) . However, CO-BRA, real-time PCR-based methods, and bisulfite-SNuPE-IP RP HPLC assay determine methylation level at only limited CpG sites. Methylation density determined by BiPS is considered as quantitative but cannot be validated if a sample shows a heterogeneous singlestranded conformational polymorphism (SSCP) pattern. Even though the ERMA can determine overall methylation level within a region containing a number of CpG sites, it requires radioactive labeling of DNA samples and subsequent cumbersome purification step of the radiolabeled products.
Accordingly, we developed a novel nonisotopic quantitative methylation assay by nucleotide incorporation (MANIC), which reveals overall methylation density within an amplified region. The quantification is achieved by measuring incorporated dCTP in accordance with the amount of methylated cytosine residues on the bisulfite-converted strand of the PCR product. We designed MANIC to determine relative methylation density of a region within O 6 -methylguanine-DNA methyltransferase (MGMT) gene promoter (14) and studied sensitivity and accuracy of our method using control DNA derived from cloned DNA. Then, to validate the accuracy of our method in clinical samples, we analyzed relative methylation density in colorectal cancer (CRC) tissues and corresponding normal mucosal tissues in comparison with one of the quantitative methods called BiPS.
Methylation assay by nucleotide incorporation:
a quantitative assay for regional CpG methylation density 
MATERIALS AND METHODS

Human Tissue Samples and DNA Preparation
Tumor tissues from CRC patients and corresponding normal mucosal samples were surgically removed at Okayama University Hospital. The samples were stored frozen before use. Peripheral blood mononuclear cells (PBMCs) were obtained from healthy individuals. The DNA was extracted using the standard phenol-chloroform procedure, precipitated by ethanol and dissolved in Tris EDTA (TE; 10 mM Tris, pH 8.0, 1 mM EDTA) buffer.
Bisulfite Modification
Sodium bisulfite modification of genomic DNA (up to 1 μg) was carried out using CpGenome™ DNA Modification Kit (Intergen, Purchase, NY, USA) according to the manufacturer's instructions.
Bisulfite-PCR
A region within the exon 1 of the MGMT promoter from nucleotides (nt) 1026 to 1128 (in the numbering system described in Reference 14) encompassing 12 CpG sites was amplified ( Figure 1 ) by bisulfite-converted sense strand-specific PCR primers, 5′-TTTIG-GATATGTTGGGATAGTT-3′ (forward primer) and 5′-ACCCAAACACTCA-CCAAATC-3′ (reverse primer). To amplify all the converted DNA alleles regardless of the methylation status, the forward primer contains an inosine at a position corresponding to a CpG-associated cytosine residue (nt 1029). The PCR mixture contained 1× HotStarTaq ® Master Mix (Qiagen, Hilden, Germany), 400 nM of each primer, and bisulfite-modified DNA (10-40 ng) in a final volume of 50 µL. The PCR was performed on the GeneAmp ® PCR System 9700 (Applied Biosystems, Foster City, CA, USA) with the following cycling parameters: an activation step of HotStarTaq at 95°C for 15 min, followed by 45 cycles of 94°C for 30 s, 57°C for 30 s, and 72°C for 20 s, with a final extension step of 72°C for 2 min. The amplified products were confirmed by 2.5% agarose gel electrophoresis with ethidium bromide staining.
Preparation of a Full-and Nonmethylation Control DNA for MANIC
We used PCR products generated from plasmids, pHo2/5 as a full-methylation control and pHSC4-2/9 as a nonmethylation control, that were both constructed by cloning PCR product amplified from bisulfite-treated DNA extracted from human tissues. Sequence analysis revealed that pHSC4-2/9 contained no cytosines, because of the bisulfite-conversion of all cytosines, but that pHo2/5 contained 12 cytosines at CpG-associated cytosine sites protected from the conversion by the methylation of the original DNA. The PCR from the cloned DNA was performed with the following cycling parameters: an initial denaturation at 94°C for 2 min, followed by 25 cycles of 94°C for 30 s, 45°C for 30 s, and 72°C for 20 s, with a final extension step of 72°C for 2 min using ExTaq™ DNA polymerase (Takara Shuzo, Shiga, Japan).
MANIC Protocol
The PCR products were purified and quantitated using MinElute™ PCR Purification Kit (Qiagen) and PicoGreen ® dsDNA Quantitation Kit (Molecular Probes, Eugene, OR, USA), respectively, and subjected to methylation analysis by MANIC. Incorporation of fluorescein-labeled dCTP was carried out by incubating 10 μL of reaction containing 1× Thermo Sequenase™ buffer (Amersham Biosciences, Piscataway, NJ, USA), 20 μM of each dNTP (Roche Diagnostics GmbH, Mannheim, Germany), 5 μM of fluorescein-12-dCTP (PerkinElmer Lifesciences, Boston, MA, USA), 0.2 μM of 5′-biotinylated primer (5′-GGATATGTTGGGATAGTT-3′), 0.32 U/μL of Thermo Sequenase, and 100 fmol of sample DNA at 95°C for 2 min for denaturation, at 50°C for 30 s for annealing, and finally at 60°C for 5 min for extension, using a 96-well PCR plate on the programmable thermal controller PTC-100 (MJ Research, Watertown, MA, USA). After 90 μL TE buffer were added to each extended product and mixed, 90 μL of the diluted product were transferred into a well of a streptoavidin-coated microplate (Roche Diagnostics GmbH) and then incubated at room temperature for 30 min. The wells were washed with 1× Tris-buffered saline (TBS; 25 mM Tris, pH 7.4, 137 mM NaCl, 23 mM KCl) buffer with 0.1% Tween ® 20. Then, 100 μL of 150 mU/mL antifluorescein alkaline phosphatase antibody (Roche Diagnostics GmbH) in SuperBlock™ Blocking solution (Pierce Biotechnology, Rockford, IL, USA) in TBS buffer were added and incubated at room temperature for 10 min. After washing the wells, 100 µL of chemiluminescent substrate, Tropix ® CDP-Star ® with Sapphire-II™ (Applied Biosystems) were added to each well and incubated at room temperature for 5 min. Consequent luminescence was measured by the microplate MLX™ Luminometer (Dynex Technologies, Chantilly, VA, USA).
BiPS Analysis
The bisulfite-PCR products used for MANIC were also analyzed by BiPS (12) . Twenty femtomoles of each product were mixed with 10 μL of solution containing 95% deinonized formamide, 10 mM EDTA (pH 8.0), and 0.02% crystal violet. After denaturation at 80°C for 2 min, the samples were applied to a 6% polyacrylamide in 1× Tris-borate EDTA (TBE; 90 mM Tris-borate, pH 8.2, 1 mM EDTA) buffer (acrylamide/bisacrylamide, 29:1, 20 cm × 20 cm × 0.5 mm). Electrophoresis was performed at 15 W for 50 or 60 min at 4°C with 1× TBE as running buffer. The gel was stained with SYBR ® Gold (Molecular Probes), scanned, and then analyzed with the fluorescent image analyzer FMBIO ® II Multi-View and FMBIO Analysis version 6.0 software (Hitachi Software Engineering, Yokohama, Kanagawa, Japan), respectively. For determination of band intensity, the background fluorescence from the gel was subtracted.
Methylation-Specific PCR
Methylation status within the exon 1 of the MGMT promoter was analyzed by MSP as described previously (15) . The forward primers specific to methylated allele and unmethylated allele are depicted in Figure 1 . The amplified products were confirmed by 2.5% agarose gel electrophoresis with ethidium bromide staining.
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Immunohistochemical Analysis of MGMT Protein
Immunohistochemical (IH) staining using mouse anti-MGMT monoclonal antibody, clone MT3.1 (BD Biosciences Pharmingen, San Diego, CA, USA), was performed as described elsewhere (16) . Because the normal staining pattern for MGMT was nuclear, tumor cells that exhibited an absence of nuclear staining in the presence of non-neoplastic cells with nuclear staining were considered to have an abnormal pattern. 
RESULTS
Sensitivity and Quantitative Accuracy of MANIC
Because we could not detect significant increase in fluorescent signal from fluorescein-incorporated DNA captured on the solid phase, we employed an enzyme immunoassay (EIA)-like detection system to enhance the signal. We designed MANIC system to determine the methylation density within a region of MGMT exon 1, which contains 12 CpG-associated cytosines ( Figure 1 ). Various parameters, such as sequences and annealing temperature of the biotinylated-extension primer, amount of template DNA, and concentration of labeled and unlabeled nucleotides, could be critical variants for the performance of MANIC. We optimized those conditions utilizing full-and nonmethylation control DNAs and validated sensitivity and accuracy of the assay using mixtures of these controls. The MANIC revealed high sensitivity to detect 1.25% methylated DNA at least (Figure 2A ) and exhibited excellent correlation between luminescence intensity and the theoretical percent methylation (R 2 = 0.9857) with the coefficient of variation ranging from 1.7% to 16% ( Figure 2B ).
MANIC Analysis of the CRC Samples
PCR products derived from bisulfitetreated genomic DNA were assessed by MANIC. The signals of PBMCs from healthy individuals were significantly higher than those of nonmethylation control DNA ( Figure 3A) , suggesting the presence of low-level methylation corresponding to 10%-20% methylation according to the calibration curve. However, the widely used MSP analysis of the MGMT promoter (15) did not reveal any methylation in any of these samples (data not shown). One possible explanation for that is the increased background signal due to PCR byproducts derived from bisulfite-treated genomic DNA. Although the PCR products can be sufficiently amplified from cloned DNA with annealing temperature at 45°C, those amplified from bisulfite-treated genomic DNA required hot-start PCR technique with higher annealing temperature (approximately 57°C) and increased number of cycles (approximately 45 cycles) to obtain specific and sufficient amount of PCR products, suggesting that the PCR from bisulfite-treated DNA is critical. Thus, accumulated byproducts that could not be detected on agarose gel electrophoresis with ethidium bromide staining could cause increased background signal. Therefore, we adopted a term "methylation index," which refers to the ratio of incorporated labeled dCTP signal of a sample relative to that of the full-methylation control DNA, in order to express the relative methylation RESEARCH REPORT density in human samples. According to the definition, the mean value of methylation index of the normal PBMC DNA from nine individuals was calculated as 0.155 ± 0.018 (sd) ( Figure 3A) .
We next analyzed methylation density of the MGMT promoter in CRC tissues and the corresponding normal mucosal samples from 12 patients by MANIC ( Figure 3B) . A diverse spectrum of methylation index was observed in the tumor tissues. On the contrary, most normal tissues exhibited lower methylation index compared to the corresponding tumor samples except one case ( Figure 3B , no.80).
MSP and MGMT Expression Analyses of CRC Samples
We also conducted a qualitative methylation analysis by MSP (15) and an analysis of MGMT protein expression by IH staining and correlated those with the results obtained from MANIC ( Figure 3B ). As we tentatively determined a methylation index of 0.3 as the cut-off value for MANIC-positive, two samples (111N and 190T) exhibited MSP-positive but MANIC-negative, and one sample (291N) exhibited MSP-negative but MANIC-positive among the 24 samples examined from 12 cases.
Correlation Between MANIC and BiPS Analyses
We also developed a quantitative BiPS assay for the same region within the MGMT promoter to examine propriety of the MANIC of clinical samples by comparison of the two methods. As shown in Figure 4A , among the shifted bands detected by BiPS, we found that the appearance of band 2 and disappearance of band 1 were both concordant with the amount of the methylated DNA. Therefore, the proportion of the methylated DNA was represented by an equation, I 2 /(I 1 + I 2 ), where I 1 and I 2 indicate the intensities of band 1 and band 2, respectively. Thus, we calculated the proportion of the shifted bands in all of the tumor samples and 1 normal mucosal tissue (291N) and compared these data with the results of MANIC analysis ( Figure 4B) . As a result, we found a high concordance between the two methods (R 2 = 0.9276).
DISCUSSION
It has been indicated that the methylation density of promoter CpG islands is more important than methylation occurred at a specific single CpG site for gene silencing (17) . Nevertheless, it has been very difficult to measure the level of methylation in a target area containing multiple CpG sites. Here we report a novel quantitative methylation assay (MANIC) based on nucleotide incorporation by primer extension. This microplate-based assay does not require cumbersome electrophoresis or handling of radioactive materials. The control experiments proved that MANIC was highly sensitive and ac- In contrast to the study of the methylation status in cell lines, studies of those in tumor cells from human neoplastic tissue samples are extremely difficult because of the heterogeneity of the tumor tissue. Although MSP has been used to screen samples for evidence of promoter hypermethylation, this method is seriously limited in its utility by the hybridization specificity of the primers upon which its use depends and potentially gives false-positive and false-negative results. In addition, MSP is so sensitive that it can detect small population of the cells having methylation in the promoter sequence of interest. The present study showed principally concordant results between the MANIC and the MSP except three samples (111N, 190T, and  291N ). MANIC did not detect a significant level of methylation in 111N and 190T, whereas both samples showed MSP-positive. If minor subpopulation of the cells within those specimens exhibits MGMT promoter hypermethylation, theoretically, a sensitive MSP assay could detect methylation in these samples. An IH study on both 111N and 190T revealed focal (111N) or broad (190T) loss of MGMT expression. However, the BiPS results as well clearly showed that methylation density in both samples was not high as a whole. It was also possible that the positive results by MSP were simply due to false results when the CpG sites specified by the MSP primer happened to be methylated, while other CpG sites were not methylated. In the case of 291N, MANIC exhibited a low but significant level of the methylation with a negative MSP and a positive IH. A possible explanation is that the methylated subpopulation of cells could not be identified by IH as a loss of staining and the MSP was false-negative. However, the results obtained by BiPS strongly support that MANIC did detect low but substantial methylation density of the MGMT promoter in the sample 291N.
MANIC merely shows the average value of methylation density in each sample. Namely, the method is basically not able to discriminate between partially methylated DNA and a mixture of fully methylated and unmethylated ones. In that case, the combination of microdissection and MANIC could provide a more informative analysis. In fact, most of the colorectal tumors that we have examined turned out to be anything but homogeneous. However, we cannot be sure that even the most careful microdissection of tumor samples from which the DNA had been extracted prior to bisulfite treatment will suffice to ensure the reliability and reproducibility of the assay so far. This issue remains as a matter to be argued further.
MANIC showed a higher methylation index in bisulfite-PCR product derived from normal tissue samples compared with the nonmethylation control DNA, which does not indicate the presence of elevated methylation density but may reflect some artifacts generated during the bisulfite-PCR. Given that the designed primer sequences or selected DNA polymerase for PCR can cause increased background signal, these parameters must be carefully optimized for the individual target region.
MANIC is basically highly sensitive and accurate and is applicable to any sequence containing an arbitrary number of 
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CpG sites in principle. Moreover, it can be easily adapted to an automated system because this assay needs neither gel electrophoresis nor radioactive materials and is applicable to a standard microplate format. Although we attempted to detect fluorescence directly from the incorporated fluorophore, fluorescein-labeled dCTP could not allow us to detect significant increase in the signal intensities for most samples. Therefore, we employed signal amplification by the EIA-like method. However, other strategies of fluorescent signal amplification, [e.g., energy-transfer dyes known as BigDye™ (Applied Biosystems)] (18) may contribute to improve signal-to-noise ratio and allow us to eliminate the EIA-like procedure. Furthermore, primer extension on the solid phase should enable us to adapt MANIC to a high-throughput system.
Loss of MGMT expression was indicated as a consequence of the hypermethylation of the promoter in cell lines (19, 20) and primary human neoplasia (15) . MGMT has been thought to be an ideal target for biochemical modulation (21) (22) (23) (24) . Furthermore, it was reported that the methylation status of the MGMT promoter is associated with overall survival and response to alkylating agents in gliomas (25) . In CRC, methylation of the MGMT promoter characterizes a subset of the cancers with low-level DNA microsatellite instability (16) . However, clinical implications of regional methylation within MGMT promoter in CRC are still unclear. Thus, accumulation of data studying the associations between the methylation density of the MGMT promoter and the clinical outcome by MANIC may lead us to establish robust prognostic and diagnostic tools for CRC. Thus, MANIC is potentially applicable to the high-throughput system for larger samples and should contribute to comprehensive understandings of the cancer epigenetics.
